SK279237B6 - Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl - Google Patents

Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl Download PDF

Info

Publication number
SK279237B6
SK279237B6 SK3449-92A SK344992A SK279237B6 SK 279237 B6 SK279237 B6 SK 279237B6 SK 344992 A SK344992 A SK 344992A SK 279237 B6 SK279237 B6 SK 279237B6
Authority
SK
Slovakia
Prior art keywords
alcohol
amperoside
effect
piperazinecarboxamide
fluorophenyl
Prior art date
Application number
SK3449-92A
Other languages
English (en)
Slovak (sk)
Other versions
SK344992A3 (en
Inventor
Anders Bj�Rk
Erik Christensson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of SK344992A3 publication Critical patent/SK344992A3/sk
Publication of SK279237B6 publication Critical patent/SK279237B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SK3449-92A 1991-03-22 1992-03-23 Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl SK279237B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9100860A SE9100860D0 (sv) 1991-03-22 1991-03-22 New use
PCT/SE1992/000182 WO1992016211A1 (en) 1991-03-22 1992-03-23 New use of diphenylbutyl-piperazinecarboxamides in the treatment of substance disorders

Publications (2)

Publication Number Publication Date
SK344992A3 SK344992A3 (en) 1995-11-08
SK279237B6 true SK279237B6 (sk) 1998-08-05

Family

ID=20382242

Family Applications (1)

Application Number Title Priority Date Filing Date
SK3449-92A SK279237B6 (sk) 1991-03-22 1992-03-23 Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl

Country Status (24)

Country Link
US (2) US5434156A (ja)
EP (1) EP0538422B1 (ja)
JP (1) JP3221611B2 (ja)
KR (1) KR100196674B1 (ja)
AT (1) ATE199057T1 (ja)
AU (1) AU653797B2 (ja)
BG (1) BG61829B1 (ja)
BR (1) BR9204969A (ja)
CA (1) CA2083505C (ja)
CZ (1) CZ282222B6 (ja)
DE (1) DE69231680T2 (ja)
DK (1) DK0538422T3 (ja)
EE (1) EE02973B1 (ja)
ES (1) ES2154261T3 (ja)
GR (1) GR3035805T3 (ja)
HU (2) HU9203632D0 (ja)
IE (1) IE920920A1 (ja)
NO (1) NO301311B1 (ja)
PT (1) PT100279B (ja)
RO (1) RO109702B1 (ja)
RU (1) RU2095062C1 (ja)
SE (1) SE9100860D0 (ja)
SK (1) SK279237B6 (ja)
WO (1) WO1992016211A1 (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
JP3571114B2 (ja) * 1995-07-11 2004-09-29 ポーラ化成工業株式会社 麻薬拮抗剤
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2433833C (en) * 2001-01-17 2009-06-02 Juan Jose Legarda Ibanez Use of flumazenil in developing a drug for the treatment of alcohol dependence
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
JP2005522436A (ja) 2002-02-08 2005-07-28 グラクソ　グループ　リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
WO2005102342A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006024471A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
EP1888071A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of drug-induced sexual dysfunction
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
JP2009513604A (ja) * 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
RS54398B1 (en) * 2006-05-09 2016-04-28 Sprout Pharmaceuticals, Inc. THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
WO2008006838A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900270A1 (ru) * 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
SK344992A3 (en) 1995-11-08
PT100279A (pt) 1993-07-30
KR100196674B1 (ko) 1999-06-15
DK0538422T3 (da) 2001-05-07
RU2095062C1 (ru) 1997-11-10
US5618817A (en) 1997-04-08
AU1428092A (en) 1992-10-21
WO1992016211A1 (en) 1992-10-01
JPH05507731A (ja) 1993-11-04
BG97108A (bg) 1994-03-24
NO301311B1 (no) 1997-10-13
CA2083505C (en) 2003-06-10
EE02973B1 (et) 1997-04-15
HUT64696A (en) 1994-02-28
PT100279B (pt) 1999-06-30
EP0538422A1 (en) 1993-04-28
NO924502D0 (no) 1992-11-23
HU217833B (hu) 2000-04-28
KR930700108A (ko) 1993-03-13
ATE199057T1 (de) 2001-02-15
AU653797B2 (en) 1994-10-13
GR3035805T3 (en) 2001-07-31
BG61829B1 (bg) 1998-07-31
CA2083505A1 (en) 1992-09-23
CZ282222B6 (cs) 1997-06-11
RO109702B1 (ro) 1995-05-30
US5434156A (en) 1995-07-18
JP3221611B2 (ja) 2001-10-22
EP0538422B1 (en) 2001-02-07
IE920920A1 (en) 1992-09-23
DE69231680D1 (de) 2001-03-15
NO924502L (no) 1992-11-23
HU9203632D0 (en) 1993-03-29
BR9204969A (pt) 1993-07-27
SE9100860D0 (sv) 1991-03-22
DE69231680T2 (de) 2001-06-07
ES2154261T3 (es) 2001-04-01
CZ344992A3 (en) 1994-02-16

Similar Documents

Publication Publication Date Title
SK279237B6 (sk) Použitie amperozidu, 4-[4,4-bis(4-fluórfenyl)butyl
IE83379B1 (en) New use of diphenylbutylpiperazinecarboxamides in the treatment of substance abuse
KR101477043B1 (ko) 디스키네시아의 치료 또는 예방제
US5565455A (en) Method for treating substance abuse disorders
WO1992014464A1 (en) Use of sigma receptor antagonists for treatment of cocaine abuse
US5629336A (en) Use of glycine/NMDA receptor ligands for the treatment of drug dependence and withdrawal
US6221858B1 (en) Pyridyl-and pyrimidyl-piperazines in the treatment of substance abuse disorders
AU629688B2 (en) Slowly dissociating (tight binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine, amphetamine and phencyclidine antagonists
US20010053786A1 (en) Methods for treating addictive disorders
CN1758912A (zh) 药物·物质依赖治疗药
MXPA98009265A (en) Piridil- and pyrimidil-piperazines in the treatment of disorders from the abuse of sustain
PT97961B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de 4-{bis-(halogenofenil)-metileno}-1-piperidinilo apropriadas para o tratamento do vicio de ingestao de drogas que originam habituacao